Abstract
Cardiomyopathies are categorized as extrinsic, being caused by external factors, such as hypertension, ischemia, inflammation, valvular dysfunction, or as intrinsic, which correspond to myocardial diseases without identifiable external causes. These so called primary cardiomyopathies can be categorized in four main forms: hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Cardiomyopathies are diagnosed by clinical expression, echocardiography, electrocardiography, non-invasive imaging, and sometimes by cardiac catheterization to rule out external causes as ischemia. The two main forms of primary cardiomyopathies are the hypertrophic and dilated cardiomyopathies. Most of hypertrophic cardiomyopathy and 20-50% of dilated cardiomyopathy are familial showing a wide genetic and phenotypic heterogeneity. This review presents the current knowledge on the causative genes, molecular mechanisms and the genotype–phenotype relations of hypertrophic and dilated cardiomyopathies.
Keywords: Cardiomyopathy, hypertrophy, dilatation, genetics, mutation
Current Pharmaceutical Biotechnology
Title:Genetics of Hypertrophic and Dilated Cardiomyopathy
Volume: 13 Issue: 13
Author(s): Felix W. Friedrich and Lucie Carrier
Affiliation:
Keywords: Cardiomyopathy, hypertrophy, dilatation, genetics, mutation
Abstract: Cardiomyopathies are categorized as extrinsic, being caused by external factors, such as hypertension, ischemia, inflammation, valvular dysfunction, or as intrinsic, which correspond to myocardial diseases without identifiable external causes. These so called primary cardiomyopathies can be categorized in four main forms: hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Cardiomyopathies are diagnosed by clinical expression, echocardiography, electrocardiography, non-invasive imaging, and sometimes by cardiac catheterization to rule out external causes as ischemia. The two main forms of primary cardiomyopathies are the hypertrophic and dilated cardiomyopathies. Most of hypertrophic cardiomyopathy and 20-50% of dilated cardiomyopathy are familial showing a wide genetic and phenotypic heterogeneity. This review presents the current knowledge on the causative genes, molecular mechanisms and the genotype–phenotype relations of hypertrophic and dilated cardiomyopathies.
Export Options
About this article
Cite this article as:
W. Friedrich Felix and Carrier Lucie, Genetics of Hypertrophic and Dilated Cardiomyopathy, Current Pharmaceutical Biotechnology 2012; 13 (13) . https://dx.doi.org/10.2174/1389201011208062467
DOI https://dx.doi.org/10.2174/1389201011208062467 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Perioperative Management of Obese Parturients
Current Women`s Health Reviews Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Taurine-Diabetes Interaction: From Involvement to Protection
Current Diabetes Reviews Texture Spectrum Coupled with Entropy and Homogeneity Image Features for Myocardium Muscle Characterization
Current Bioinformatics Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Current Pharmaceutical Design Targeted Nucleic Acid Delivery to Mitochondria
Current Gene Therapy Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Thioredoxin-1 is a Novel and Attractive Therapeutic Approach for Various Diseases Including Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Antiarrhythmic Potential of Drugs Targeting the Cardiac Ryanodine Receptor Ca<sup>2+</sup> Release Channel: Case Study of Dantrolene
Current Pharmaceutical Design Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry